Eli Lilly (LLY)

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Investing for the long-term requires a different strategy.

PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.

The stock has soared 400% in recent years.

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T...

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

Wall Street is getting more bullish on the pharma giant's shares.

Don't sleep on these medical device leaders.

The stock is down, but it isn't out yet.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri...

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.

This key factor didn't exist when Buffett first gave the advice, but does that change its appeal?

Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug.

Shares of Eli Lilly have risen by over 40% since the company last reported earnings.

The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth.

Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near.

Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.

The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.

Lilly offers investors safety and growth.

Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

This biotech might have a bright future, but it'll need to survive against the incumbents to do so.

Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.